Belly fat is often the last to go and the most frustrating to shift. There is a reason it resists, and there is a growing body of research on the peptides being studied around fat metabolism. Here is an overview.

Why visceral fat is different

The fat around the abdomen includes visceral fat, which is metabolically active and linked in research to insulin resistance and inflammation. It responds to overall energy balance, hormones and stress, which is why targeted exercises alone do not selectively remove it. Whole-body fat loss is what the literature supports.

Peptides studied around fat metabolism

Beyond the GLP-1 class, researchers have examined other compounds in preclinical and early clinical settings. 5-Amino-1MQ has been investigated for its role in inhibiting the enzyme NNMT, which is involved in adipocyte energy metabolism (studies such as Neelakantan et al., 2018, in cellular and animal models). AOD-9604, a fragment of growth hormone, has been studied for lipolytic activity. These remain research compounds, and human evidence varies widely in stage and quality.

What the evidence supports

The strongest human data for reducing overall and abdominal fat still centres on the GLP-1 and dual or triple agonist trials, which consistently reduce body weight and, in imaging sub-studies, visceral fat. Other fat-metabolism peptides are earlier in the research pipeline.

The honest picture

Belly fat resists because it is tied to whole-body physiology, so the research focuses on systemic approaches rather than spot reduction. For the best-documented mechanism, see GLP-1 peptides and weight-loss research and research on body-recomposition peptides.

Research disclaimer▾

Alle informatie op deze pagina is bedoeld voor laboratoriumonderzoek en in-vitro studies. Geen humane consumptie. Geen medische claims. Producten zijn niet goedgekeurd door EMA of FDA voor therapeutisch gebruik.